Tyler Zeronda, Chief Financial Officer of Yarrow Bioscience, Inc., filed a Form 4 on October 30, 2026, disclosing the acquisition of a stock option to purchase 156,115 shares of common stock, with a transaction date of October 29, 2026.

Key Highlights

  • Reporting person: Tyler Zeronda, Chief Financial Officer of Yarrow Bioscience, Inc.
  • Security acquired: A stock option (right to buy) covering 156,115 shares of common stock, acquired on October 29, 2026.
  • Exercise price: $20 per share, with the option expiring on October 29, 2036.
  • Price paid for option: $0, as disclosed in the filing.
  • Vesting schedule: One quarter vests on July 28, 2027; the remaining three quarters vest in equal monthly installments over the following three years, subject to continued service.
  • Resulting derivative holdings: 156,115 derivative securities beneficially owned following the reported transaction, held directly.

Yarrow Bioscience CFO Receives Stock Option Grant in October 2026

According to the Form 4 filed with the SEC on October 30, 2026, Tyler Zeronda, serving as Chief Financial Officer of Yarrow Bioscience, Inc. (NASDAQ:YARW), was granted a stock option on October 29, 2026. The option represents the right to purchase 156,115 shares of the issuer's common stock at an exercise price of $20 per share, with an expiration date of October 29, 2036. The filing reports the transaction code as "A," indicating acquisition, and states the price of the derivative security as $0.

The filing describes the vesting terms through an explanatory footnote: "one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date." The option is held directly by Zeronda, and following the reported transaction, the filing lists 156,115 derivative securities beneficially owned. No non-derivative securities transactions were reported in Table I of the filing.

The filing was submitted by one reporting person and was not indicated as an amendment to a prior form. No deemed execution date separate from the transaction date was listed. The form was signed by Tyler Zeronda on October 30, 2026.

What Was Disclosed

The filing disclosed that CFO Tyler Zeronda of Yarrow Bioscience received a stock option to buy 156,115 shares at $20 per share, expiring October 29, 2036, with a four-year vesting schedule contingent on continued service.